Abstract 4367184: Association of natriuretic peptide concentration with lifetime risk of heart failure in adults with diabetes mellitus: a pooled cohort analysis

Background: Natriruetic peptide (NP) screening is recommended for HF prevention in diabetes mellitus (DM), with NT-proBNP >125 pg/mL considered abnormal. However, evidence supporting this threshold is derived primarily from shorter-term studies. Lifetime risk (LTR) estimates for HF across NT-proBNP concentrations in DM is unknown. Methods: Participant-level data from 6 prospective cohorts (ARIC, MESA, CHS, FOS, FHS Generation 3, CRIC) and the Look AHEAD trial control group were pooled excluding participants with prevalent HF or ASCVD at baseline. Participants were stratified according to well-established NP thresholds ( Figure) . LTR of HF was determined at different index ages using the pratical incidence estimator macro with modified Kaplan-Meier methods that uses age as a time scale and mortality as a competing risk. A positive control group of adults with DM and prevalent CVD was analyzed separately. Results: Among 5,986 participants (age 61 y, 45% male, 25% Black), 1,134 developed HF over 79,347 person-years (14.3 per 1,000 person-years). At index age 55 y, the LTR of HF through 90 years was 34.4%. Lifetime risk of HF increased progressively across increasing NT-proBNP categories at each index age ( Figure 1A and 1B ). At index age 55 y, the LTR estimate for the NT-proBNP >125 pg/mL category (48.7%) was comparable to the positive control group with prevalent CVD (n = 1,687; 51.7%). LTR of HF was higher in Black (vs. non-Black) adults at every category with detectable NT-proBNP and was comparable to prevalent CVD at lower thresholds (50-125 pg/ml) ( Figure 1B ). LTR of HF among adults with low short-term HF risk (based on WATCH-DM or 10-y HF PREVENT risk scores) and NT-proBNP >125 pg/mL was high and comparable with the prevalent CVD group. Adding NT-proBNP to 30-year PREVENT HF risk score substantially improved LTR prediction performance (AUROC for 30-year risk: 0.569 to 0.685, p<0.001). Conclusions: In adults with DM, higher NT-proBNP concentrations identify higher LTR of HF, with the highest risk noted among those with concentrations >125 pg/ml supporting the current guideline recommended screening thresholds to discriminate lifetime risk. Lifetime risk of HF associated with NT-proBNP concentrations vary by race with disporporationtely high risk observed among Black adults.

Authors

Institutions

Publication Details

Journal
Circulation
Published
2025-11-03
DOI
https://doi.org/10.1161/circ.152.suppl_3.4367184
Primary Topic
GDF15 and Related Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 4367184: Association of natriuretic peptide concentration with lifetime risk of heart failure in adults with diabetes mellitus: a pooled cohort analysis

John Wilkins, Alain G. Bertoni, Matthew W. Segar, Colby Ayers et al.
Circulation
GDF15 and Related Biomarkers
article

Abstract 4367184: Association of natriuretic peptide concentration with lifetime risk of heart failure in adults with diabetes mellitus: a pooled cohort analysis

John Wilkins, Alain G. Bertoni, Matthew W. Segar, Colby Ayers, Antoni Bayés‐Genís, Rodica Pop‐Busui, Ambarish Pandey, Kershaw V. Patel, Robin P. F. Dullaart, James Louis Januzzi, James A. de Lemos, Christie Mitchell Ballantyne, Muthiah Vaduganathan, Mark A. Espeland, Christopher R. deFilippi
article en

Abstract

Background: Natriruetic peptide (NP) screening is recommended for HF prevention in diabetes mellitus (DM), with NT-proBNP >125 pg/mL considered abnormal. However, evidence supporting this threshold is derived primarily from shorter-term studies. Lifetime risk (LTR) estimates for HF across NT-proBNP concentrations in DM is unknown. Methods: Participant-level data from 6 prospective cohorts (ARIC, MESA, CHS, FOS, FHS Generation 3, CRIC) and the Look AHEAD trial control group were pooled excluding participants with prevalent HF or ASCVD at baseline. Participants were stratified according to well-established NP thresholds ( Figure) . LTR of HF was determined at different index ages using the pratical incidence estimator macro with modified Kaplan-Meier methods that uses age as a time scale and mortality as a competing risk. A positive control group of adults with DM and prevalent CVD was analyzed separately. Results: Among 5,986 participants (age 61 y, 45% male, 25% Black), 1,134 developed HF over 79,347 person-years (14.3 per 1,000 person-years). At index age 55 y, the LTR of HF through 90 years was 34.4%. Lifetime risk of HF increased progressively across increasing NT-proBNP categories at each index age ( Figure 1A and 1B ). At index age 55 y, the LTR estimate for the NT-proBNP >125 pg/mL category (48.7%) was comparable to the positive control group with prevalent CVD (n = 1,687; 51.7%). LTR of HF was higher in Black (vs. non-Black) adults at every category with detectable NT-proBNP and was comparable to prevalent CVD at lower thresholds (50-125 pg/ml) ( Figure 1B ). LTR of HF among adults with low short-term HF risk (based on WATCH-DM or 10-y HF PREVENT risk scores) and NT-proBNP >125 pg/mL was high and comparable with the prevalent CVD group. Adding NT-proBNP to 30-year PREVENT HF risk score substantially improved LTR prediction performance (AUROC for 30-year risk: 0.569 to 0.685, p<0.001). Conclusions: In adults with DM, higher NT-proBNP concentrations identify higher LTR of HF, with the highest risk noted among those with concentrations >125 pg/ml supporting the current guideline recommended screening thresholds to discriminate lifetime risk. Lifetime risk of HF associated with NT-proBNP concentrations vary by race with disporporationtely high risk observed among Black adults.

CirculationVol. 152(Suppl_3)
Northwestern University (US), University of Maryland, Baltimore (US), Brigham and Women's Hospital (US), University of Groningen (NL), Baylor College of Medicine (US), Massachusetts General Hospital (US), Southwestern Medical Center (US), Methodist Hospital (US), Michigan United (US), Badalona Serveis Assistencials (ES), Southwestern Medical Center (US), Wake Forest University (US), The University of Texas Southwestern Medical Center (US)
Openalex Percentile: Top 54%
GDF15 and Related Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.